SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

A Vaccine Against Group B Streptococcus: Recent Advances

Carreras-Abad, C; Ramkhelawon, L; Heath, PT; Le Doare, K (2020) A Vaccine Against Group B Streptococcus: Recent Advances. INFECTION AND DRUG RESISTANCE, 13. pp. 1263-1272. ISSN 1178-6973 https://doi.org/10.2147/IDR.S203454
SGUL Authors: Le Doare, Kirsty

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (507kB) | Preview

Abstract

Group B streptococcus (GBS) causes a high burden of neonatal and infant disease globally. Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and infant GBS disease and has been identified as a priority by the World Health Organisation (WHO). GBS serotype-specific polysaccharide – protein conjugate vaccines are at advanced stages of development, but a large number of participants would be required to undertake Phase III clinical efficacy trials. Efforts are therefore currently focused on establishing serocorrelates of protection in natural immunity studies as an alternative pathway for licensure of a GBS vaccine, followed by Phase IV studies to evaluate safety and effectiveness. Protein vaccines are in earlier stages of development but are highly promising as they might confer protection irrespective of serotype. Further epidemiological, immunological and health economic studies are required to enable the vaccine to reach its target population as soon as possible.

Item Type: Article
Additional Information: © 2020 Carreras-Abad et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution–Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Keywords: Group B streptococcus, Streptococcus agalactiae, maternal vaccines, maternal immunisation, neonatal sepsis, infant sepsis, 1103 Clinical Sciences, 1115 Pharmacology and Pharmaceutical Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: INFECTION AND DRUG RESISTANCE
ISSN: 1178-6973
Dates:
DateEvent
29 April 2020Published
10 March 2020Accepted
Publisher License: Creative Commons: Attribution-Noncommercial 3.0
Web of Science ID: WOS:000529520300001
URI: https://openaccess.sgul.ac.uk/id/eprint/111949
Publisher's version: https://doi.org/10.2147/IDR.S203454

Statistics

Item downloaded times since 19 May 2020.

Actions (login required)

Edit Item Edit Item